Merck Reports Result of Keytruda (pembrolizumab) in P-III KEYNOTE-048 Study as a 1L Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

 Merck Reports Result of Keytruda (pembrolizumab) in P-III KEYNOTE-048 Study as a 1L Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Merck Reports Result of Keytruda (pembrolizumab) in P-III KEYNOTE-048 Study as a 1L Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Shots:

  • The P-III KEYNOTE-048 study results involves assessing of Keytruda + CT (carboplatin/cisplatin + 5-FU) and Keytruda as monothx. vs EXTREME regimen in 882 patients with recurrent or metastatic HNSCC, whose tumor expressed CPS≥20 & CPS ≥1, presented at ASCO 2019
  • The P-III KEYNOTE-048 study results: @ CPS≥20 & CPS ≥1 for combination, 40% & 35% reduction in death; OS (14.7 & 13.6 vs 11 & 10.4 mos.); ORR (42.9% & 36.4% vs 38.2% & 35.7%); mDOR (7.1 & 6.7 vs 4.2 & 4.3 mos.); for monthx, OS (11.5 vs 10.7mos.); ORR (16.9% vs 36.0%); mDOR (22.6 vs 4.5mos.) respectively
  • Keytruda is an anti PD-1 therapy, inhibits the interaction of PD-1 and its ligands, PD-L1 and PD-L2 by activating T-lymphocytes, currently evaluating in 1000+ clinical studies for multiple cancers and has received FDA’s PR to sBLA with its expected PDUFA date on Jun 10, 2019

Click here to read full press release/ article | Ref: Merck | Image: Daily Mail          

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post